167 related articles for article (PubMed ID: 19711075)
41. Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of normal polyclonal T cells and T lymphocyte clones derived early after allogenic bone marrow transplantation.
Bruserud O; Pawelec G
Cancer Immunol Immunother; 1996 Mar; 42(3):133-40. PubMed ID: 8640841
[TBL] [Abstract][Full Text] [Related]
42. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
43. [Studies on generation of cytotoxic T lymphocytes against oral squamous carcinoma by gene-transduction of a co-stimulatory molecule, CD80].
Mogi S
Kokubyo Gakkai Zasshi; 1999 Mar; 66(1):107-17. PubMed ID: 10332153
[TBL] [Abstract][Full Text] [Related]
44. Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.
Han Y; Ye A; Bi L; Wu J; Yu K; Zhang S
Cancer Sci; 2014 Aug; 105(8):933-42. PubMed ID: 24890519
[TBL] [Abstract][Full Text] [Related]
45. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Li L; Schmitt A; Reinhardt P; Greiner J; Ringhoffer M; Vaida B; Bommer M; Vollmer M; Wiesneth M; Döhner H; Schmitt M
Cancer Immun; 2003 Jul; 3():8. PubMed ID: 12862419
[TBL] [Abstract][Full Text] [Related]
46. Differential modulation of immune recognition molecules by interleukin-7 in human acute leukaemias.
Costello RT; Mallet F; Chambost H; Sainty D; Gastaut JA; Olive D
Eur Cytokine Netw; 1999 Mar; 10(1):87-96. PubMed ID: 10210778
[TBL] [Abstract][Full Text] [Related]
47. Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells.
Vereecque R; Saudemont A; Depil S; Corm S; Andrieux J; Soenen-Cornu V; Quesnel B
Cancer Immunol Immunother; 2004 Sep; 53(9):793-8. PubMed ID: 15098140
[TBL] [Abstract][Full Text] [Related]
48. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
49. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
50. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma.
Rudy W; Gückel B; Siebels M; Lindauer M; Meuer SC; Moebius U
Int Immunol; 1997 Jun; 9(6):853-60. PubMed ID: 9199968
[TBL] [Abstract][Full Text] [Related]
51. Enhancement of immunogenicity of Jeg3 cells by ectopic expression of HLA-A*0201 and CD80.
Koc S; Kather A; Markert UR; Dürst M; Schneider A; Kaufmann AM
Am J Reprod Immunol; 2003 Sep; 50(3):243-53. PubMed ID: 14629030
[TBL] [Abstract][Full Text] [Related]
52. Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts.
Tao Q; Pan Y; Wang Y; Wang H; Xiong S; Li Q; Wang J; Tao L; Wang Z; Wu F; Zhang R; Zhai Z
Int J Cancer; 2015 Nov; 137(10):2384-93. PubMed ID: 25866142
[TBL] [Abstract][Full Text] [Related]
53. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia.
Zhong RK; Rassenti LZ; Kipps TJ; Chen J; Law P; Yu JF; Ball ED
Biol Blood Marrow Transplant; 2002; 8(10):557-68. PubMed ID: 12434951
[TBL] [Abstract][Full Text] [Related]
54. AML blasts variably express interleukin 2 receptor alpha, beta or gamma chains without measurable effects on proliferation, cytokine message expression or surface expression of adhesion molecules upon stimulation with interleukin 2.
Weidmann E; Brieger J; Bergmann L; Hoelzer D; Mitrou PS
Leuk Res; 1995 Jul; 19(7):469-76. PubMed ID: 7637393
[TBL] [Abstract][Full Text] [Related]
55. Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow.
Cao H; Kim DH; Howard A; Moz H; Wasnik S; Baylink DJ; Chen CS; Reeves ME; Mirshahidi S; Xiao J; Francis O; Marcucci G; Xu Y
Neoplasia; 2021 Dec; 23(12):1252-1260. PubMed ID: 34775232
[TBL] [Abstract][Full Text] [Related]
56. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
Bruserud O; Ulvestad E
Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
[TBL] [Abstract][Full Text] [Related]
57. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia.
Westers TM; Stam AG; Scheper RJ; Regelink JC; Nieuwint AW; Schuurhuis GJ; van de Loosdrecht AA; Ossenkoppele GJ
Cancer Immunol Immunother; 2003 Jan; 52(1):17-27. PubMed ID: 12536236
[TBL] [Abstract][Full Text] [Related]
58. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission.
Torelli GF; Guarini A; Palmieri G; Breccia M; Vitale A; Santoni A; Foa R
Br J Haematol; 2002 Feb; 116(2):299-307. PubMed ID: 11841430
[TBL] [Abstract][Full Text] [Related]
59. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Cheuk AT; Guinn BA
Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
